On July 31, 2020 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, reported that the Company will present at the Proactive Investors One2One Virtual Event on August 4, 2020 (Press release, Genprex, JUL 31, 2020, View Source [SID1234562637]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Rodney Varner, Genprex’s Chairman and Chief Executive Officer, will deliver a Company overview and provide updates on its product pipeline, including its lead drug candidate, GPX-001 (formerly referred to as "Oncoprex" immunogene therapy), which received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for use in combination with AstraZeneca’s Tagrisso in late stage lung cancer patients with EGFR mutations whose tumors progress on Tagrisso. Mr. Varner will also provide an overview of the Company’s preclinical diabetes gene therapy candidate that may have the potential to cure Type 1 and Type 2 diabetes.

Event: Proactive Investors One2One Virtual Event

Date: Tuesday, August 4, 2020

Time: 1:40 p.m. ET

Registration Link: https://bit.ly/2D3fpx7

The Proactive Investor One2One investor forums are designed for private investors, private client brokers, fund managers, financial institutions, hedge funds, buy and sell side analysts and journalists.